Oculis
towards the assessment of the efficacy of in patients phase acuity trial in acute optic neuritis | Oculis
Company
Deck Type
Deck date
July 2023
Slide
62 of 76
Related slides by other companies
NeuroSense Therapeutics
Investor Presentation
June 2023
phase trial design | NeuroSense Therapeutics
Avenue Therapeutics
IPO
October 2022
safety and efficacy has been demonstrated in two phase trials in over patients | Avenue Therapeutics
MAIA Biotechnology
Investor Presentation
November 2023
thio trial planned a | MAIA Biotechnology
Exscientia
Investor Day
January 2024
enabling studies complete | Exscientia
Other recent decks by Oculis
See all presentations (7 decks)
Investor Presentation
April 2024
Results
August 2023
Investor Conference
June 2023
Results
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights